# A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

> **NCT01392573** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 413 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec/liraglutide
- **DRUG:** insulin degludec

## Key facts

- **NCT ID:** NCT01392573
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-28
- **Primary completion:** 2012-10-01
- **Final completion:** 2012-10-04
- **Target enrollment:** 413 (ACTUAL)
- **Last updated:** 2019-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01392573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01392573, "A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-09-13 from https://api.ai-analytics.org/clinical/NCT01392573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*